Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego

Leading perfusion professionals to experience Inspira's FDA-cleared cardiopulmonary bypass INSPIRA™ ART100 technology at premier industry event

RA'ANANA, Israel, March 19, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira," "Inspira Technologies" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that its U.S. Food and Drug Administration-cleared life-support system, the INSPIRA™ ART100, will be showcased at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference, taking place March 19-23, 2025, at the Loews Coronado Bay Resort in San Diego, California, by their distributor Glo-Med Networks Inc ("Glo-Med").

Conference attendees will have the opportunity to explore Inspira's cutting-edge cardiopulmonary bypass technology at Glo-Med's booth. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024 for use in cardiopulmonary bypass procedures, represents an advancement in extracorporeal circulation technology.

"The AmSECT International Conference brings together leading perfusion professionals, providing an ideal platform to showcase our INSPIRA ART100 system," said Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "This event offers an excellent opportunity to further expose our innovative technology to the perfusion community. We look forward to connecting with industry experts and demonstrating how our solutions can support medical professionals."

Visitors interested in scheduling a personal meeting are welcome to contact Mr. Levi Perryman at levi@glomednet.com or visit Booth number 4.

About AmSECT 63rd International Conference

The American Society of ExtraCorporeal Technology (AmSECT) International Conference is the premier global event for perfusion professionals, focusing on advancements in extracorporeal circulation, patient care, and perfusion education. The event will feature the latest medical technologies, research, and discussions shaping the future of perfusion.

About Inspira Technologies

Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500 (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.

For more information, visit: https://inspira-technologies.com

Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk
inspira@arxadvisory.com

SOURCE Inspira Technologies